drug_type
RELEVANT_DRUG
intervention_type
Therapeutic cancer vaccine
drug_description
Therapeutic cancer vaccine that is a glycoconjugate linking the tumor-associated carbohydrate antigen Globo H to the carrier protein CRM197; designed to induce strong anti–Globo H humoral and cellular immunity against Globo H–expressing tumor cells.
nci_thesaurus_concept_id
C119745
nci_thesaurus_definition
A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.
drug_mesh_term
Cancer Vaccines
drug_category
IMMUNOGENIC PROTEIN
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
OBI-833 is a glycoconjugate therapeutic cancer vaccine linking the Globo H tumor-associated carbohydrate antigen to the carrier protein CRM197. With adjuvant support (e.g., OBI-821), it induces strong anti–Globo H humoral and helper T-cell responses; elicited antibodies mediate immune effector functions (e.g., complement activation and ADCC) against Globo H–expressing tumor cells, reducing tumor growth.
drug_name
OBI-833
nct_id_drug_ref
NCT06490198